2024
Ponatinib vs. asciminib in post–second-generation tyrosine kinase inhibitor therapy for chronic-phase chronic myeloid leukemia: a matching-adjusted indirect comparison
Garcia-Gutierrez V, Huang F, Ashaye A, Dalal M, Laliman-Khara V, Breccia M, Rutherford M, Moradian H, Patos P, Jabbour E. Ponatinib vs. asciminib in post–second-generation tyrosine kinase inhibitor therapy for chronic-phase chronic myeloid leukemia: a matching-adjusted indirect comparison. Frontiers In Oncology 2024, 14: 1455378. PMID: 39634261, PMCID: PMC11615674, DOI: 10.3389/fonc.2024.1455378.Peer-Reviewed Original ResearchMatching-adjusted indirect comparisonChronic-phase chronic myeloid leukemiaChronic myeloid leukemiaT315I mutationCP-CMLMyeloid leukemiaTyrosine kinase inhibitor therapyIndirect comparisonsResponse rateBaseline responsesSecond-generation TKIsT315I mutation statusKinase inhibitor therapyThird-line therapyMedical literature databasesInhibitor therapyMutation subgroupsMutation statusPatient-level dataEfficacy outcomesBaseline characteristicsMMR rateProportion Z testClinical trialsCumulative rate
2017
RimabotulinumtoxinB in sialorrhea: systematic review of clinical trials
Dashtipour K, Bhidayasiri R, Chen JJ, Jabbari B, Lew M, Torres-Russotto D. RimabotulinumtoxinB in sialorrhea: systematic review of clinical trials. Journal Of Clinical Movement Disorders 2017, 4: 9. PMID: 28593050, PMCID: PMC5460542, DOI: 10.1186/s40734-017-0055-1.Peer-Reviewed Original ResearchAdverse eventsClinical trialsSystematic reviewDose-dependent adverse eventsMethodsA systematic literature reviewMild transient dysphagiaMost adverse eventsComparative clinical studyTreatment of patientsMedical literature databasesDry mouthTransient dysphagiaMild weaknessClinical studiesToxin effectsLiterature databasesBoNTIndividual studiesTrialsTreatmentPrimary publicationsDosesSystematic literature reviewSignificant benefitsReview
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply